retatrutide triple agonist glp-1 gip glucagon phase 3 2025 The Science Behind Retatrutide: A New Hope for Obesity and Diabetes – Prime Lab Peptides Triple Agonism Based Therapies for

prescribed off-label for weight loss Estimated retail price: $950$1,200/month Zepbound (tirzepatide) FDA approved for weight loss Estimated retail price: $1,080$1,200/month Mounjaro (tirzepatide) FDA approved for type 2 diabetes

A 2025 meta-analysis suggested a slightly increased pancreatitis risk overall, but no strong evidence for increased pancreatic cancer, with some nuance around background medications

It is a triple-hormone receptor agonist peptide that simultaneously activates GLP-1, GIP, and glucagon (GCG) receptors

J Am Coll Nutr 1994;13:6-21

Understanding these variables helps contextualise any changes observed during treatment and prevents unnecessary anxiety